GlassScriptPhysician profile
Bridget M Clark
NPI 1760141352
$668.09
in general payments reported to CMS, 2019-2025
12 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $116 · 2023: $13.72 · 2024: $539.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Education: $288 · Food and Beverage: $264.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Education | $287.99 |
| Food and Beverage | $264.37 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $304.29 | 2024 | Xospata |
| Jazz Pharmaceuticals INC. | $102.54 | 2021 | |
| Novartis Pharmaceuticals Corporation | $58.75 | 2024 | |
| Pfizer INC. | $34.38 | 2023-2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $30.55 | 2024 | Alunbrig |
| Daiichi Sankyo INC. | $28.38 | 2024 | Enhertu |
| Ipsen Biopharmaceuticals, INC | $23.62 | 2024 | Onivyde, Somatuline Depot |
| Pharmacosmos Therapeutics INC. | $21.67 | 2024 | Monoferric |
| Merck Sharp & Dohme LLC | $17.93 | 2024 | Welireg, Keytruda |
| Genzyme Corporation | $17.85 | 2024 | |
| Celgene Corporation | $14.94 | 2024 | Reblozyl |
| Genentech USA, INC. | $13.19 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bridget Clark listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.